よむ、つかう、まなぶ。
会議資料 (127 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00046.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第68回 5／25）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；IV-177
CHARACTERISTICS. 2022 Jun.
３）
Siemens Healthcare Limited. MetaTrace FDG Solution for injection. SUMMARY OF
PRODUCT CHARACTERISTICS. 2022 Sep.
４）
Advanced
Accelerator
Applications.
GLUSCAN®
600
MBq/ml
Injektionslösung.
Fachinformation (Zusammenfassung der Merkmale des Arzneimittels/SmPC). 2022 Dec.
５）
ADVANCED ACCELERATOR APPLICATIONS MOLECULAR IMAGING FRANCE
SAS. GLUSCAN 600 MBq/mL, solution injectable. RESUME DES CARACTERISTIQUES DU
PRODUIT. 2024 Apr.
６）
CURIUM INTERNATIONAL. FLUDESOXYGLUCOSE (18F) CURIUM 185 MBq/mL
solution injectable. RESUME DES CARACTERISTIQUES DU PRODUIT. 2023 Sep.
７）
Betrains A, Boeckxstaens L, Moreel L, Wright W, Blockmans D, Laere K, et al. Higher
diagnostic yield of 18F-FDG PET in inflammation of unknown origin compared to fever of
unknown origin. Eur J Intern Med. 2023;110:71-6.
８）
Meller J, Altenvoerde G, Munzel U, Jauho A, Behe M, Gratz S, et al. Fever of unknown
origin: prospective comparison of [18F]FDG imaging with a double-head coincidence camera
and gallium-67 citrate SPET. Eur J Nucl Med. 2000;27(11):1617-25.
９）
Lorenzen J, Buchert R, Bohuslavizki K H. Value of FDG PET in patients with fever of
unknown origin. Nucl Med Commun. 2001;22(7):779-83.
１０） Kjaer A, Lebech AM, Eigtved A, Højgaard L. Fever of unknown origin: prospective
comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. Eur J Nucl
Med Mol Imaging. 2004;31(5):622-6.
１１） Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW, Oyen WJ. Clinical value
of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or
inflammation. Eur J Nucl Med Mol Imaging. 2004;31(1):29-37.
１２） Buysschaert I, Vanderschueren S, Blockmans D, Mortelmans L, Knockaert D. Contribution
of (18)fluoro-deoxyglucose positron emission tomography to the work-up of patients with fever
of unknown origin. Eur J Intern Med. 2004;15(3):151-6.
１３） Bleeker-Rovers CP, Vos FJ, Mudde AH, Dofferhoff ASM, de Geus-Oei LF, Rijnders AJ, et
al. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic
protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging.
2007;34(5):694-703.
１４） Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of
18F-FDG PET/CT. J Nucl Med. 2008;49(12):1980-5.
１５） Balink H, Collins J, Bruyn GA, Gemmel F. F-18 FDG PET/CT in the diagnosis of fever of
unknown origin. Clin Nucl Med. 2009;34(12):862-8.
１６） Federici L, Blondet C, Imperiale A, Sibilia J, Pasquali J-L, Pflumio F, et al. Value of
(18)F-FDG-PET/CT in patients with fever of unknown origin and unexplained prolonged
57
127/370
CHARACTERISTICS. 2022 Jun.
３）
Siemens Healthcare Limited. MetaTrace FDG Solution for injection. SUMMARY OF
PRODUCT CHARACTERISTICS. 2022 Sep.
４）
Advanced
Accelerator
Applications.
GLUSCAN®
600
MBq/ml
Injektionslösung.
Fachinformation (Zusammenfassung der Merkmale des Arzneimittels/SmPC). 2022 Dec.
５）
ADVANCED ACCELERATOR APPLICATIONS MOLECULAR IMAGING FRANCE
SAS. GLUSCAN 600 MBq/mL, solution injectable. RESUME DES CARACTERISTIQUES DU
PRODUIT. 2024 Apr.
６）
CURIUM INTERNATIONAL. FLUDESOXYGLUCOSE (18F) CURIUM 185 MBq/mL
solution injectable. RESUME DES CARACTERISTIQUES DU PRODUIT. 2023 Sep.
７）
Betrains A, Boeckxstaens L, Moreel L, Wright W, Blockmans D, Laere K, et al. Higher
diagnostic yield of 18F-FDG PET in inflammation of unknown origin compared to fever of
unknown origin. Eur J Intern Med. 2023;110:71-6.
８）
Meller J, Altenvoerde G, Munzel U, Jauho A, Behe M, Gratz S, et al. Fever of unknown
origin: prospective comparison of [18F]FDG imaging with a double-head coincidence camera
and gallium-67 citrate SPET. Eur J Nucl Med. 2000;27(11):1617-25.
９）
Lorenzen J, Buchert R, Bohuslavizki K H. Value of FDG PET in patients with fever of
unknown origin. Nucl Med Commun. 2001;22(7):779-83.
１０） Kjaer A, Lebech AM, Eigtved A, Højgaard L. Fever of unknown origin: prospective
comparison of diagnostic value of 18F-FDG PET and 111In-granulocyte scintigraphy. Eur J Nucl
Med Mol Imaging. 2004;31(5):622-6.
１１） Bleeker-Rovers CP, de Kleijn EM, Corstens FH, van der Meer JW, Oyen WJ. Clinical value
of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or
inflammation. Eur J Nucl Med Mol Imaging. 2004;31(1):29-37.
１２） Buysschaert I, Vanderschueren S, Blockmans D, Mortelmans L, Knockaert D. Contribution
of (18)fluoro-deoxyglucose positron emission tomography to the work-up of patients with fever
of unknown origin. Eur J Intern Med. 2004;15(3):151-6.
１３） Bleeker-Rovers CP, Vos FJ, Mudde AH, Dofferhoff ASM, de Geus-Oei LF, Rijnders AJ, et
al. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic
protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging.
2007;34(5):694-703.
１４） Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of
18F-FDG PET/CT. J Nucl Med. 2008;49(12):1980-5.
１５） Balink H, Collins J, Bruyn GA, Gemmel F. F-18 FDG PET/CT in the diagnosis of fever of
unknown origin. Clin Nucl Med. 2009;34(12):862-8.
１６） Federici L, Blondet C, Imperiale A, Sibilia J, Pasquali J-L, Pflumio F, et al. Value of
(18)F-FDG-PET/CT in patients with fever of unknown origin and unexplained prolonged
57
127/370